Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. TOT BIOPHARM International Company Limited
  6. Summary
    1875   HK0000545266

TOT BIOPHARM INTERNATIONAL COMPANY LIMITED

(1875)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
4.16 4.01 4.1 4.1 4.1 Last
98000 76800 20000 96800 50800 Volume
+0.24% -3.61% +2.24% 0.00% 0.00% Change
Estimated financial data (e)
Sales 2021 118 M 18,5 M 18,5 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Sales 2022 266 M 41,8 M 41,8 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 2 015 M 317 M 316 M
Capi. / Sales 2021 17,1x
Capi. / Sales 2022 7,57x
Nbr of Employees 354
Free-Float 50,9%
More Financials
Company
TOT BIOPHARM International Company Limited is a company mainly engaged in the development and commercialization of oncology drugs and therapies. The Company has a portfolio of oncology drug candidates, which include monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs. 
More about the company
All news about TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
12/01TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin« (TAB008, Bevacizum..
PR
12/01TOT Biopharm's Lung Cance Drug Bags Marketing Approval in China; Shares Rally 5%
MT
11/23TOT Biopharm International Forms Pharma Sales JV With China Resources Pharmaceutical
MT
11/09TOT Biopharm Narrows Loss in January-September as Revenue Doubles; Shares Rally 4%
MT
09/16TOT BIOPHARM International Company Limited Reports Unaudited Consolidated Earnings Resu..
CI
08/12TOT BIOPHARM INTERNATIONAL : 2021 Interim Revenue Surges 78% to RMB23.13 million
AQ
08/12TOT BIOPHARM International Company Limited Reports Unaudited Consolidated Earnings Resu..
CI
05/31TOT BIOPHARM INTERNATIONAL : Cancer Drug Wins Registration, Marketing Approvals in China; ..
MT
05/31Tot Biopharm International Company Limited Announces Drug Registration Approval for Tem..
CI
05/13TOT BIOPHARM INTERNATIONAL : Wins Approval to Sell Appetite Stimulant in China
MT
05/13TOT BIOPHARM INTERNATIONAL : Voluntary announcement - marketing approval for megestrol ace..
PU
05/11TOT BIOPHARM INTERNATIONAL : Trims Loss in Q1
MT
05/10TOT BIOPHARM INTERNATIONAL : Certain unaudited financial information for the three months ..
PU
05/10TOT BIOPHARM International Company Limited Reports Unaudited Consolidated Earnings Resu..
CI
03/24TOT BIOPHARM INTERNATIONAL : Trims Loss in 2020 over Lower Expenses; Shares Drop 4%
MT
More news
News in other languages on TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
11/09TOT Biopharm réduit sa perte en janvier-septembre et double ses revenus ; les actions a..
More news
Chart TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
Duration : Period :
TOT BIOPHARM International Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,35 CNY
Average target price 6,08 CNY
Spread / Average Target 81,4%
Managers and Directors
Jun Liu CEO, Executive Director & Chief Scientific Officer
Shan Fu Non-Executive Chairman
Ming Liu Chief Medical Officer & Vice General Manager
Lan Hu Independent Non-Executive Director
Lijun Sun Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
TOT BIOPHARM INTERNATIONAL COMPANY LIMITED-7.03%317
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625